2024-04-012025-03-312025-03-31false13975332GW OSTEOPATHY SURREY LTD2025-12-0186900falseiso4217:GBPxbrli:pure139753322024-03-31139753322025-03-31139753322024-04-012025-03-31139753322023-03-31139753322024-03-31139753322023-04-012024-03-3113975332bus:SmallEntities2024-04-012025-03-3113975332bus:AuditExempt-NoAccountantsReport2024-04-012025-03-3113975332bus:AbridgedAccounts2024-04-012025-03-3113975332bus:PrivateLimitedCompanyLtd2024-04-012025-03-3113975332core:WithinOneYear2025-03-3113975332core:AfterOneYear2025-03-3113975332core:WithinOneYear2024-03-3113975332core:AfterOneYear2024-03-3113975332core:ShareCapital2025-03-3113975332core:SharePremium2025-03-3113975332core:RevaluationReserve2025-03-3113975332core:OtherReservesSubtotal2025-03-3113975332core:RetainedEarningsAccumulatedLosses2025-03-3113975332core:ShareCapital2024-03-3113975332core:SharePremium2024-03-3113975332core:RevaluationReserve2024-03-3113975332core:OtherReservesSubtotal2024-03-3113975332core:RetainedEarningsAccumulatedLosses2024-03-3113975332core:LandBuildings2025-03-3113975332core:PlantMachinery2025-03-3113975332core:Vehicles2025-03-3113975332core:FurnitureFittings2025-03-3113975332core:OfficeEquipment2025-03-3113975332core:NetGoodwill2025-03-3113975332core:IntangibleAssetsOtherThanGoodwill2025-03-3113975332core:ListedExchangeTraded2025-03-3113975332core:UnlistedNon-exchangeTraded2025-03-3113975332core:LandBuildings2024-03-3113975332core:PlantMachinery2024-03-3113975332core:Vehicles2024-03-3113975332core:FurnitureFittings2024-03-3113975332core:OfficeEquipment2024-03-3113975332core:NetGoodwill2024-03-3113975332core:IntangibleAssetsOtherThanGoodwill2024-03-3113975332core:ListedExchangeTraded2024-03-3113975332core:UnlistedNon-exchangeTraded2024-03-3113975332core:LandBuildings2024-04-012025-03-3113975332core:PlantMachinery2024-04-012025-03-3113975332core:Vehicles2024-04-012025-03-3113975332core:FurnitureFittings2024-04-012025-03-3113975332core:OfficeEquipment2024-04-012025-03-3113975332core:NetGoodwill2024-04-012025-03-3113975332core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3113975332core:ListedExchangeTraded2024-04-012025-03-3113975332core:UnlistedNon-exchangeTraded2024-04-012025-03-3113975332core:MoreThanFiveYears2024-04-012025-03-3113975332core:Non-currentFinancialInstruments2025-03-3113975332core:Non-currentFinancialInstruments2024-03-3113975332dpl:CostSales2024-04-012025-03-3113975332dpl:DistributionCosts2024-04-012025-03-3113975332core:LandBuildings2024-04-012025-03-3113975332core:PlantMachinery2024-04-012025-03-3113975332core:Vehicles2024-04-012025-03-3113975332core:FurnitureFittings2024-04-012025-03-3113975332core:OfficeEquipment2024-04-012025-03-3113975332dpl:AdministrativeExpenses2024-04-012025-03-3113975332core:NetGoodwill2024-04-012025-03-3113975332core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3113975332dpl:GroupUndertakings2024-04-012025-03-3113975332dpl:ParticipatingInterests2024-04-012025-03-3113975332dpl:GroupUndertakingscore:ListedExchangeTraded2024-04-012025-03-3113975332core:ListedExchangeTraded2024-04-012025-03-3113975332dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-04-012025-03-3113975332core:UnlistedNon-exchangeTraded2024-04-012025-03-3113975332dpl:CostSales2023-04-012024-03-3113975332dpl:DistributionCosts2023-04-012024-03-3113975332core:LandBuildings2023-04-012024-03-3113975332core:PlantMachinery2023-04-012024-03-3113975332core:Vehicles2023-04-012024-03-3113975332core:FurnitureFittings2023-04-012024-03-3113975332core:OfficeEquipment2023-04-012024-03-3113975332dpl:AdministrativeExpenses2023-04-012024-03-3113975332core:NetGoodwill2023-04-012024-03-3113975332core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3113975332dpl:GroupUndertakings2023-04-012024-03-3113975332dpl:ParticipatingInterests2023-04-012024-03-3113975332dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-012024-03-3113975332core:ListedExchangeTraded2023-04-012024-03-3113975332dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-012024-03-3113975332core:UnlistedNon-exchangeTraded2023-04-012024-03-3113975332core:NetGoodwill2025-03-3113975332core:IntangibleAssetsOtherThanGoodwill2025-03-3113975332core:LandBuildings2025-03-3113975332core:PlantMachinery2025-03-3113975332core:Vehicles2025-03-3113975332core:FurnitureFittings2025-03-3113975332core:OfficeEquipment2025-03-3113975332core:AfterOneYear2025-03-3113975332core:WithinOneYear2025-03-3113975332core:ListedExchangeTraded2025-03-3113975332core:UnlistedNon-exchangeTraded2025-03-3113975332core:ShareCapital2025-03-3113975332core:SharePremium2025-03-3113975332core:RevaluationReserve2025-03-3113975332core:OtherReservesSubtotal2025-03-3113975332core:RetainedEarningsAccumulatedLosses2025-03-3113975332core:NetGoodwill2024-03-3113975332core:IntangibleAssetsOtherThanGoodwill2024-03-3113975332core:LandBuildings2024-03-3113975332core:PlantMachinery2024-03-3113975332core:Vehicles2024-03-3113975332core:FurnitureFittings2024-03-3113975332core:OfficeEquipment2024-03-3113975332core:AfterOneYear2024-03-3113975332core:WithinOneYear2024-03-3113975332core:ListedExchangeTraded2024-03-3113975332core:UnlistedNon-exchangeTraded2024-03-3113975332core:ShareCapital2024-03-3113975332core:SharePremium2024-03-3113975332core:RevaluationReserve2024-03-3113975332core:OtherReservesSubtotal2024-03-3113975332core:RetainedEarningsAccumulatedLosses2024-03-3113975332core:NetGoodwill2023-03-3113975332core:IntangibleAssetsOtherThanGoodwill2023-03-3113975332core:LandBuildings2023-03-3113975332core:PlantMachinery2023-03-3113975332core:Vehicles2023-03-3113975332core:FurnitureFittings2023-03-3113975332core:OfficeEquipment2023-03-3113975332core:AfterOneYear2023-03-3113975332core:WithinOneYear2023-03-3113975332core:ListedExchangeTraded2023-03-3113975332core:UnlistedNon-exchangeTraded2023-03-3113975332core:ShareCapital2023-03-3113975332core:SharePremium2023-03-3113975332core:RevaluationReserve2023-03-3113975332core:OtherReservesSubtotal2023-03-3113975332core:RetainedEarningsAccumulatedLosses2023-03-3113975332core:AfterOneYear2024-04-012025-03-3113975332core:WithinOneYear2024-04-012025-03-3113975332core:Non-currentFinancialInstrumentscore:CostValuation2024-04-012025-03-3113975332core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-012025-03-3113975332core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-012025-03-3113975332core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-012025-03-3113975332core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-012025-03-3113975332core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-012025-03-3113975332core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3113975332core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3113975332core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3113975332core:Non-currentFinancialInstrumentscore:CostValuation2025-03-3113975332core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-3113975332core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-3113975332core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-3113975332core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-3113975332core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-3113975332core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-3113975332core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-3113975332core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-3113975332core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3113975332core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3113975332core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3113975332core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3113975332core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3113975332core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3113975332core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3113975332core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3113975332core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3113975332bus:Director12024-04-012025-03-31

GW OSTEOPATHY SURREY LTD

Registered Number
13975332
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2025

GW OSTEOPATHY SURREY LTD
Company Information
for the year from 1 April 2024 to 31 March 2025

Director

Webster, Gemma Lucinda

Registered Address

Centora Ltd
Ripley Lane
West Horsley
KT24 6JT

Registered Number

13975332 (England and Wales)
GW OSTEOPATHY SURREY LTD
Balance Sheet as at
31 March 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets31,856-
1,856-
Current assets
Debtors625-
Cash at bank and on hand67,78660,787
68,41160,787
Creditors amounts falling due within one year(61,051)(60,345)
Net current assets (liabilities)7,360442
Total assets less current liabilities9,216442
Net assets9,216442
Capital and reserves
Called up share capital11
Profit and loss account9,215441
Shareholders' funds9,216442
The financial statements were approved and authorised for issue by the Director on 1 December 2025, and are signed on its behalf by:
Webster, Gemma Lucinda
Director
Registered Company No. 13975332
GW OSTEOPATHY SURREY LTD
Notes to the Financial Statements
for the year ended 31 March 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:
2.Average number of employees

20252024
Average number of employees during the year21
3.Tangible fixed assets

Total

£
Cost or valuation
Additions2,088
At 31 March 252,088
Depreciation and impairment
Charge for year232
At 31 March 25232
Net book value
At 31 March 251,856
At 31 March 24-